Advertisement

Differentielle Indikationen der neuroleptischen Akutbehandlung Schizophrener

  • J. Tegeler
Part of the Tropon-Symposium book series (BAYERZNS, volume 2)

Zusammenfassung

Untersuchungen über differentielle Indikationen der neuroleptischen Akutbehandlung müssen von zwei Voraussetzungen ausgehen:
  • Schizophrenien sind eine Gruppe von Krankheitsbildern mit heterogener Ätiologie, Pathogenese, Symptomatik und Prognose.

  • Neuroleptika wirken diagnoseübergreifend auf nosologisch unspezifische Zielsyndrome.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Angrist B, Rotrosen J, Gerhon S (1980) Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia. Psychopharmacology 72: 17–19PubMedCrossRefGoogle Scholar
  2. Aubree JC, Lader MH (1980) High and very high dosage antipsychotics: A critical review. J Clin Psychiatry 41: 341–350Google Scholar
  3. Bobon DP, Gottfries CG (1974) Clinical physiognomy of thioxanthenes. Acta Psychiat Belg 74: 441–568Google Scholar
  4. Carpenter WT, Mc Glashan TH, Strauss JS (1977) The treatment of schizophrenia without drugs. An investigation of some current assumptions. Am J Psychiatry 134: 14–20Google Scholar
  5. Cole JO, Bonato R, Goldberg SC (1968) Non-specific factors in the drug therapy of schizo-phrenic patients. In: Rickels K (ed) Non-specific factors in drug therapy. Thomas, Spring-field, Ill.Google Scholar
  6. Crow TJ (1980) Molecular pathology of schizophrenia: more than one desease process? Br Med J 280: 66–68PubMedCrossRefGoogle Scholar
  7. Davis JM, Schaffer CB, Killian GA, Kinard C, Chan C (1980) Important issues in the drug treatment of schizophrenia. Schizophr Bull 6: 70–87PubMedGoogle Scholar
  8. Delini-Stula A (1986) Neuroanatomical, neuropharmacological and neurobiochemical target systems for antipsychotic activity of neuroleptics. Pharmacopsychiatria 19: 134–139CrossRefGoogle Scholar
  9. Donlon PT (1976) High dosage neuroleptic therapy. Int Pharmacopsychiat 11: 235–245Google Scholar
  10. Frith CD, Stevens M, Johnstone EC, Crow TF (1979) Skin conductance responsitivity during acute episodes of schizophrenics as a predictor of symptomatic improvement. Psychol Med 9: 101–106PubMedCrossRefGoogle Scholar
  11. Galbrecht CR, Klett CJ (1968) Predicting response to phenothiazines: The right drug for the right patient. J Nerv Ment Dis 147: 173–183Google Scholar
  12. Gardos G (1974) Are antipsychotic drugs interchangeable? J Nerv Ment Dis 159: 343–348PubMedCrossRefGoogle Scholar
  13. Gardos G, Cole JO, Orzack MH (1973) The importance of dosage in antipsychotic drug administration — A review of dose-response studies. Psychopharmacologia 29: 221–230PubMedCrossRefGoogle Scholar
  14. Goldberg SC, Frosch WA, Drossman AK, Schooler NR, Johnson CF (1972) Prediction of response to phenothiazines in schizophrenia. A cross validation study. Arch Gen Psychiatry 26: 367–373PubMedCrossRefGoogle Scholar
  15. Goldberg SC, Schooler NR, Mattson N (1967) Paranoid and withdrawal symptoms in schizophrenia. J Nerv Ment Dis 145: 158–162PubMedCrossRefGoogle Scholar
  16. Heimann H (1977) Wirkung von Psychopharmaka und zugrundeliegende theoretische Vorstellungen. Allgemeine methodologische Probleme der klinischen Prüfung von Psychopharmaka. Pharmacopsychiatria 10: 119–129CrossRefGoogle Scholar
  17. Hollister LE (1973) Clinical use of psychotherapeutic drugs. Thomas, Springfield, Ill.Google Scholar
  18. Hollister LE, Overall JE, Bennet JL, Kimbell I, Shelton J (1967) Spezific therapeutic actions of acetophenazine, perphenazine, and benzquinamide in newly admitted schizophrenic patients. Clin Pharmacol Ther 8: 249–255PubMedGoogle Scholar
  19. Hollister LE, Overall JE, Kimbell I, Pokorny A (1974) Specific indications for different classes of phenothiazines. Arch Gen Psychiatry 30: 94–99PubMedCrossRefGoogle Scholar
  20. Hyttel J, Larsen J-J, Christensen AV, Amt J (1985) Receptorbinding profiles of neuroleptics. In: Casey DE, Chase TN, Christensen AV, Gerlach J (eds) Dyskinesia research and treatment. Psychopharmacology, Supp12. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  21. Itil TM (1977) Quantitative und qualitative EEG in Schizophrenia. Schizophr Bull 3: 61–69PubMedGoogle Scholar
  22. Judd LL, Goldstein MJ, Rodnick EH, Jackson NL (1973) Phenothiazine effects in good premorbid schizophrenics divided into paranoid-nonparanoid status. Arch Gen Psychiatry 29: 207–211PubMedCrossRefGoogle Scholar
  23. Kane JM (1985) Antipsychotic drug side effects: Their relationship to dose. J Clin Psychiatry 46: 16–21PubMedGoogle Scholar
  24. Kebabian JW, Caine DB (1979) Multiple receptors for dopamine. Nature 277: 93–96PubMedCrossRefGoogle Scholar
  25. Klein DF, Rosen B (1973) Premorbid asocial adjustment and response to phenothiazine treatment among schizophrenic in patients. Arch Gen Psychiatry 29: 480–485PubMedCrossRefGoogle Scholar
  26. Klett CJ, Moseley EC (1965) The right drug for the right patient. J Consul Clin Psychol 29: 546–551Google Scholar
  27. Lehmann E, Klieser E, Wöller W, Quadbeck H, Tegeler J, Heinrich K (1987) Experimentelle Prüfung der Wechselwirkung von Haloperidol und Schizophrenietyp. In: Heinrich K (Hrsg) Probleme der neuroleptischen Dosierung. Schattauer, StuttgartGoogle Scholar
  28. Lehmann E, Quadbeck H, Tegeler J, Fararuni M, Heinrich K (1980) Wirkungsdifferenzen bei Hoch-und Standarddosierung von Fluphenazin-Decanoat in Abhängigkeit von Patienten-Merkmalen. Pharmacopsychiatria 13: 117–129CrossRefGoogle Scholar
  29. Losonczy MF, Song IS, Mhos HC, Small NA, Davidson M, Johns CA, Davis KL (1986) Correlates of lateral ventricular size in chronic schizophrenia 1: Behavioral and treatment response measures. Am J Psychiatry 143: 976–981Google Scholar
  30. Luchins EDJ, Lewine RJ, Meltzer HY (1984) Lateral ventricular size, psychopathology, and medication response in the psychoses. Biol Psychiatry 19: 29–44PubMedGoogle Scholar
  31. Marder SR, Kammen DP van, Docherty JP, Rayner J, Bunney WE (1979) Predicting drug-free improvement in schizophrenic psychosis. Arch Gen Psychiatry 36: 1080–1085PubMedCrossRefGoogle Scholar
  32. May PRA, Dencker SJ, Liberman RP, Hubbard JW, Midha KK (1985) Ein systematischer Ansatz zur Therapieresistenz schizophrener Erkrankungen. Vortragsmanuskript Int. Schizophrenie-Symposium, München-HaarGoogle Scholar
  33. May PRA, Goldberg SC (1978) Prediction of schizophrenic patients’ response to pharmacotherapy. In: Lipton MA, DiMascio A, Killam KF (eds) Psychopharmacology: a generation of progress. Raven Press, New YorkGoogle Scholar
  34. Möller HJ, Kissling W, Zerssen D von (1983) Die prognostische Bedeutung des frühen Ansprechens schizophrener Patienten auf Neuroleptika für den weiteren stationären Behandlungsverlauf. Pharmacopsychiatria 16: 46–49PubMedCrossRefGoogle Scholar
  35. Möller HJ, Kissling W, Maurach R, Schmid W, Doerr P, Pirke K, Zerssen D von (1981) Beziehungen zwischen Haloperidol-Serumspiegel, Prolactin-Serumspiegel, antipsychotischem Effekt und extrapyramidalen Begleitwirkungen. Pharmacopsychiatria 14: 27–34Google Scholar
  36. Müller P (1987) Neuroleptische Dosierung bei therapieresistenten Schizophrenien. In: Heinrich K (Hrsg) Probleme der neuroleptischen Dosierung. Schattauer, StuttgartGoogle Scholar
  37. Murphy DL, Shiling DJ, Murray RM (1978) Psychoactive drug responder subgroups: Possible contributions to psychiatric classification. In: Lipton MA, DiMascio A, Killam KF (eds) Psychopharmacology: a generation of progress. Raven Press, New YorkGoogle Scholar
  38. Nasrallah HY, Kuperman S, Hamra BJ (1983) Clinical differences between schizophrenic patients with and without large cerebral ventricles. J Clin Psychiatry 44: 407–409PubMedGoogle Scholar
  39. Nedopil N, Pflieger R, Rüther E (1983) The prediction of acute response, remission and general outcome of neuroleptic treatment in acute schizophrenic patients. Pharmacopsychiatria 6: 195–200Google Scholar
  40. Nedopil N, Rüther E (1981) Initial improvement as predictor of outcome of neuroleptic therapy. Pharmacopsychiatria 14: 205–207PubMedCrossRefGoogle Scholar
  41. National Institute of Mental Health, Psychopharmacology Research Branch Collaborative Study Group Short Term Improvement in Schizophrenia (1968) The contribution of background factors. Am J Psychiatry 124: 900–909Google Scholar
  42. Peroutka SJ, Snyder SH (1980) Relationship of neuroleptic drug effects at brain dopamine, serotonin, adrenergic, and histamine receptors to clinical potency. Am J Psychiatry 137: 1518–1522PubMedGoogle Scholar
  43. Putten T van, May PRA (1978) Subjective response as a predictor of outcome in pharmacotherapy. Arch Gen Psychiatry 35: 477–480PubMedCrossRefGoogle Scholar
  44. Putten T van, May PRA, Marder SR, Wittmann LA (1981) Subjective response to antipsychiotic drugs. Arch Gen Psychiatry 38: 187–190PubMedCrossRefGoogle Scholar
  45. Putten T van, May PRA, Marder SR (1984) Response to antipsychotic medication: the doctor’s and the consumer’s view. Am J Psychiatry 141: 16–19PubMedGoogle Scholar
  46. Richelson E (1984) Neuroleptic affinities for human brain receptors and their use in predicting adverse effects. J Clin Psychiatry 45: 331–336PubMedGoogle Scholar
  47. Schulz SC, Sinicrope P, Kishore P (1983) Treatment response and ventricular brain enlargement in young schizophrenic patients. Psychopharmacol Bull 19: 510–512PubMedGoogle Scholar
  48. Seeman P (1982) Nomenclature of central and peripheral dopaminergic sites and receptors. Biochem Pharmacol 31: 2563–2568PubMedCrossRefGoogle Scholar
  49. Singh MM, Kay SR (1979) Dysphoric response to neuroleptic treatment in schizophrenia: its relationship to autonomic arousal and prognosis. Biol Psychiatry 14: 277–295PubMedGoogle Scholar
  50. Spadoni AJ, Smith JA (1969) Milieu therapy in schizophrenia. Arch Gen Psychiatry 20: 547–551PubMedCrossRefGoogle Scholar
  51. Sokoloff D, Martress MP, Delandre M, Schwartz JC, Protais P, Costentin J (1983) Two classes of dopamine receptors distinguishable by substituted benzamides. In: Ackenheil M, Matussek N (eds) Special aspects of psychopharmacology. Expansion Scientifique FrancaiseGoogle Scholar
  52. Tegeler J (1983) Dosierung und Verträglichkeit der Depot-und Langzeitneuroleptika. In: Pö1dinger W (Hrsg) Tegeler J 35, Tropon KölnGoogle Scholar
  53. Tegeler J, Lehmann E, Quadbeck H, Klieser E, Wöller W (1982) Experimenteller Vergleich niedriger und hoher Haloperidol-Dosen in der Behandlung akut schizophrener Patienten. Arzneimittelforsch 32 (II): 887–888Google Scholar
  54. Ungerstedt U, Herrera-Marschitz M, Stahle L, Tossman U, Zetterström T (1985) Functional classification of different dopamine receptors. In: Casey DE, Chase TN, Christensen AV, Gerlach J (eds) Dyskinesia research and treatment psychopharmacology, Suppl 2. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  55. Weinberger TR, Bigelow LB, Kleinman JE (1980) Cerebral ventricular enlargement and poor response to treatment. Arch Gen Psychiatry 37: 11–13PubMedCrossRefGoogle Scholar
  56. Woggon B (1980) Veränderungen der psychopathologischen Symptomatik während 20tägiger antidepressiver oder neuroleptischer Behandlung. Psychiatr Clin (Basel) 13: 150–164Google Scholar
  57. Woggon B (1983) Prognose der Psychopharmakotherapie. Enke, StuttgartGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • J. Tegeler

There are no affiliations available

Personalised recommendations